Commercial Readiness Pharvaris is building a commercial infrastructure in anticipation of a potential launch of deucrictibant IR for on demand HAE treatment, supported by multi year funding that enhances opportunities for partnerships, payer strategy, and market access preparations.

Pipeline Momentum Phase three pivotal data and CREAATE enrollment ongoing for prophylaxis and on demand indications create time sensitive opportunities to engage clinical and market access stakeholders ahead of NDA timelines.

Oral Advantage Pharvaris's focus on oral bradykinin B2 receptor antagonists offers a patient preferred route versus injectable therapies, creating a strong value proposition for specialty pharmacies, clinics, and patient support programs.

Global Expansion Based in Switzerland with ongoing conference activity and a plan to scale commercial operations, Pharvaris could pursue EU and US market access partnerships, distributors, and KOL led education to drive adoption across HAE and AAE C1INH.

Financing Backbone Recent funding activity and a cash runway into 2028 provide the financial capacity to build a robust field force, digital engagement, and market access initiatives to accelerate sales readiness.